Preexisting antiviral immunity promoted the clearance of injected oncolytic Ad from tumors, but had no effect on antitumor efficacy. Strikingly, the repeated treatment with oncolytic Ad has strong therapeutic effect on relapsed tumors or tumors insensitive to the primary viral therapy.
Introduction
Oncolytic viruses (OVs) are self-replicating, theoretically tumor selective, and possess an ability to directly lyse cancer cells. OVs are being developed as an attractive therapeutics for cancers (1) . Viral replication is quite immunogenic. An active host immune response against the viruses which rapidly eliminates the virus had been considered as an important barrier to the successful cancer virotherapy. Indeed, several studies showed that suppressing the immune system enhanced the efficacy of oncolytic adenovirus (Ad) (2, 3) . However, there have been accumulating evidence that the virus-induced immune activation can generate innate and adaptive immune responses that are critical to mediating the antitumor responses. Recently, preclinical and clinical data suggested that the virotherapy might in fact act as cancer immunotherapy (4, 5) . The interactions between oncolytic viruses, tumor cells and the immune system are critical to the outcome of antitumor efficacy of OVs.
Like many OVs, Ad replication is species-specific and human Ads replicate poorly in cells from most other species like mice and rats. Consequently, most published efficacy data have come from immune-deficient mice bearing human tumor xenografts.
These models cannot adequately address the effect of the host immune system on the vector, tumor, as well as the toxicity and biodistribution of the vector in normal tissues.
The Syrian hamster has been characterized as a suitable immunocompetent, replicationpermissive animal model for the assessment of human oncolytic Ads (6, 7) . Intratumoral (2) . However, the pre-immunization, which induced a persistent high-level of neutralizing anti-Ad antibody and disabled the detection of the infectious virus injected in tumors, had no effect on the antitumor efficacy of oncolytic Ad in immunocompetent animals. In the pre-immunized tumor-bearing animals, CP treatment had no effect on tumor growth, although the titer of neutralizing anti-Ad antibody stayed steady at all time points, and tumors had moderate amount of virus (8) . These results suggest that curative viral oncolysis on its own probably only occurs in the instance when tumors are completely devoid of any virus defense system. On the other hand, promotion of immune responses by arming oncolytic Ad with immune-stimulatory molecules in the immunocompetent hosts significantly enhanced antitumor effects (9) (10) (11) . Thus, the host immune responses will probably be critical to the efficacy of oncolytic virotherapy, although it also mediate the rapid viral elimination.
In recent years, a lot of clinical data in cancer immunotherapy clearly demonstrated that T cell response is the dominant fighter against cancers. The cellular antiviral immune response may limit efficacy of virotherapy by eliminating tumor infection via clearance of infected tumor cells. Alternatively, clearance of infected tumor cells may play a key role in tumor regression. Some studies showed that T cell response triggered by oncolytic virotherapy included virus-specific cytotoxic activity, which might play a role in tumor therapy (12) (13) (14) . Although T cells are major components for both anti-virus and antitumor immunity, they have been rarely studied in oncolytic Ad therapy in immunocompetent, replication-permissive hosts. In this study, we evaluated the effects of T cells in oncolytic Ad therapy by using an anti-Syrian hamster CD3 monoclonal antibody that can delete T cells in hamsters. We found that oncolytic Ad therapy induced strong virus-specific and tumor-specific T cell responses. Deletion of T cells extended the persistence of infectious virus in tumors, but almost abrogated the antitumor efficacy.
These results suggest that T cell-mediated immune responses outweigh direct oncolysis of Ad in mediating antitumor efficacy in immunocompetent hosts.
Research. 
Materials and methods

Cell lines, Viruses and reagents
The Syrian hamster pancreatic carcinoma cell line HPD-1NR was purchased from German Collection of Microorgnisms and Cell Culture, and kidney tumor cell line HAK was originally purchased from American Type Culture Collection (ATCC). JH293, the human kidney epithelial cell line transformed with Ad5 DNA, was obtained from Cancer Research UK Central Cell Services, London, United Kingdom. All cell lines were cultured in basal medium (HPD-NR and HAK, RPMI 1640; JH293, DMEM) supplemented with 10% fetal bovine serum (Hyclone), 2 mmol/L L-glutamine (Hyclone), 100 IU/mL penicillin, and 50 μg/mL streptomycin. Cells were tested negative for mycoplasma. Cells were not further authenticated.
Wild-type adenovirus type 5 (Ad5) and E1A-deleted Ad5 (dl312) were from Sino-British Research Centre, Zhengzhou University, and grown on HEK-293 cells as previously described (15) .
The mouse monoclonal antibody (mAb) against Syrian hamster CD3e (clone 4F11, IgG1 isotype) and anti-KLH mAb were prepared as previously described (16) .
In vivo treatments
Four-to five-week-old female Syrian (Golden) hamsters (Mesocricetus auratus) were obtained from Vital River Corp (Beijing, China), and inoculated subcutaneously (s.c.)
with 1 x 10 6 HPD-1NR cells. The tumor-bearing animals were treated by intratumoral (i.t.) injection of Ad5 or PBS every other day for six times from day 11 after tumor inoculation. The injections were introduced through a single central tumor puncture site and 3-4 needles tracts were made radially from the center while the virus was injected as the needle was withdrawn. To delete T cells, an anti-hamster CD3 mAb (4F11) was injected intraperitoneally (i.p.) at doses of 500μg/injection every 5 days from the day before the viral therapy, and anti-KLH mAb was used as control. Tumor size was measured twice weekly using digital calipers, and tumor volume was calculated using the formula: volume = (length x width 2 xπ/6). All animal experiments were approved by the Animal Welfare and Research Ethics Committee of the Institute of Biophysics, Chinese
Academy of Sciences (Beijing, China) and were conducted in accordance with institutional and national regulations.
CTL assays
CTL assays were done as previously described with a little modification (17 
Assessment of virus in tumors
Fresh tumor tissues were homogenized and titrated on JH-293 cells to determine the 50% tissue culture infective dose (TCID50) as previously described (18) . Viral DNA levels were evaluated as previously described (16) . Results were expressed as genome copy number/gram based on the weight of tumor tissues.
Immunohistochemistry (IHC)
The harvested tumor tissues were processed and stained respectively with anti-hamster 
Detection of anti-Ad5 antibodies
Anti-Ad5 antibodies were detected as previously described (16) . The relative levels of total antibodies in all samples were shown as the value of OD 450nm .
Statistical analysis
Statistical analysis was done with GraphPad Prism 5 software. The results are expressed as means with the standard deviations (±SD) when appropriate. Differences between groups were analyzed using the two-tailed Student's t test or 2-way ANOVA. P < 0.05 (*) was considered significant, and P < 0.01 (**) was considered highly significant. To determine whether the T cell responses initiated by Ad vector results in immunological memory, the hallmark of adaptive immunity, we evaluated the cured hamsters for long-term protection by tumor rechallenge with or without T cell deletion. detected by viral replication assay remained elevated at the same level (~10 6 PFU/g or so)
in both tumors of immunocompetent and T cell-depleted animals within three days after the first viral injection. Then, in immunocompetent animals, virus levels were decreased approximately tenfold (10 5 PFU/g) by day 7. At day 11, just one day after the last viral injection, only one of three animals showed a detectable virus in tumors, which is only slightly (about twofold) higher than the detection limit (1x10 3 PFU/g). In contrast, the amount of infectious virus within tumors of T cell-deficient animals still maintained elevated (~10 7 PFU/g or so) at day 7 after the first viral injection, and then started to gradually decrease and reached to ~10 4 PFU/g by day 17. All animals in both groups had no detectable infectious virus in tumors 21 days after the first viral injection ( Fig. 2A) . viral proteins were rarely detected in tumors of both animals (Fig. 2B) . Thus, viral replication was initially similar in tumors injected with oncolytic Ad, regardless of immune status of animals. About one week later, the infectious virus and virus-infected tumor cells began to rapidly decline in immunocompetent animals compared with that in T cell-deficient hamsters. This timing suggested that the infectious virus and virusinfected tumor cells were eliminated by adaptive anti-viral immunity developed in immunocompetent animals. Although T cells deficiency allowed intratumoral virus levels to remain elevated for prolonged periods, the antitumor effects of oncolytic Ad were severely impaired in T cell-deficient hamsters (Fig. 1) . These results further support the critical role of T cells in oncolytic Ad therapy.
There was no significant difference in virus DNA levels titrated by real-time PCR between the tumors of T cell-deficient and immunocompetent hamsters. Viral DNA level remained elevated in tumor until day 17 and could not be detected at day 21 after the first viral injection (Fig.2C) . These data suggest that T cells play a major role in elimination (Fig.2D ). These data showed that the viral replication was not correlated with cytolysis in tumors even at day 7 after viral injection, while T cell response was associated with suppression of virus replication and increased apoptosis in tumors.
Overall, these results demonstrate that oncolytic Ad therapy rapidly induces T cell responses, which eliminate the virus-infected tumors cells and mediated antitumor efficacy although it also decrease the yield of infectious virus in tumors.
Oncolytic Ad therapy resulted in both tumor-and virus-specific CTL activities activity also appeared at this time point (Fig. 3A) . These results demonstrate that (Fig. 3B) . Because the viral treatment just transiently inhibited tumor growth in T cell-deficient animals (Fig. 1A) , the regression of the virus-injected right tumors suggested the therapeutic effect of anti-viral immunity. While the retarded growth of the untreated left tumors suggested the effect of anti-tumor immunity, which appeared later than that of anti-viral immunity. This result is consistent with the virus-and tumor-specific CTL activities.
Preexisting anti-Ad immunity promotes viral clearance of tumors through T cells, but has no effect on therapeutic efficacy
Research. (Fig. 4) . (Fig.5B, Right) . These data suggest that the injected infectious virus could effectively infect tumor cells before it was cleared by the preexisting anti-viral immunity. Meanwhile, it further supports that Ad genome is cleared by innate rather than adaptive immunity. Consistent with the previous study (8) , the preexisting anti-Ad immunity did not affect the antitumor efficacy of oncolytic Ad. However, T cell deletion also abrogated the antitumor effect of oncolytic Ad in pre-immunized animals (Fig. 5C) . These results further prove that T cell responses play major roles in antitumor efficacy of oncolytic Ad, even under the condition of preexisting anti-Ad immunity that can rapidly eliminate the infectious virus from tumors.
Repeated Oncolytic Ad therapy eradicates the primary therapy resistant tumors
Research. Next, we wonder if repeated oncolytic Ad therapy has therapeutic effects on the tumors that grow up from the primary oncolytic Ad therapy. To this end, tumorbearing hamsters were treated with six i.t. injections of low dosage of Ad5 (5 x 10 8 PFU/injection). Ad treatment caused complete regression of tumors in five of twenty hamsters. The other tumors just transiently shrank. 12 days after the last viral injection when the shrunk tumors started to grow, the tumor-bearing hamsters were randomly divided into two groups that were respectively treated with another six injections high dosage of Ad (2 x 10 9 PFU/injection) or PBS as control. All tumors kept growing in the PBS-treated animals. Ad treatment caused complete regression of tumors in five of eight animals. The growth of tumors was also delayed in other three hamsters (Fig. 6) . This result demonstrates that repeated oncolytic Ad therapy has strong therapeutic effect on relapsed tumors or tumors insensitive to the primary viral therapy. Most interestingly, the same treatment with high-dosage of Ad eliminated the relapsed tumors in more than 60% hamsters (Fig. 6) , versus the primary tumors in 40% hamsters (Fig. 1A) . Moreover, the relapsed tumors were at least two times bigger than the primary tumors when they were treated with Ad. This data suggests that the anti-viral recall immune response triggered by the repeated Ad therapy might have greater therapeutic effect on relapsed tumors.
Discussion
An intriguing aspect of oncolytic virotherapy is that by their very nature they potently stimulate multiple arms of the immune system. In return, the immune system exerts multiple effects on the outcome of tumor therapy: some positive, some negative. The could allow for antigen spreading and reduce local immunosuppression. So, the Adspecific T cell response appears to be an important component of Ad-mediated antitumor responses.
A majority of the human population is seropositive for Ad5, which is acquired as a childhood infection. Elimination of the vector by preexisting immunity to Ad poses a possible concern with respect to achieving significant antitumor efficacy (25) (26) (27) ).
The adaptive immune responses and, in particular, neutralizing antibodies were shown to be a common and powerful inhibitory end response to infection involving a variety of oncolytic viruses, including Ad (28-30). To study the effect of the preexisting anti-Ad immunity on the viral clearance and therapeutic efficacy of oncolytic virotherapy, we immunized the hamsters with one does of intramuscular injection of Ad. Consistent with the previous study (8) , the pre-immunization induced persistent high level of anti-Ad antibody in plasma and tumor tissues.
Correspondingly, the infectious Ad could not be detected in tumors of the preimmunized animals even at the very early time after the viral injection. However, once T cells were deleted in the pre-immunized hamsters, the infectious Ad was easily detected in the tumor tissues and showed a similar dynamic process with that in tumors of immunocompetent hamsters without pre-immunization, although T cell deletion had no effect on the titer of anti-Ad antibody in the pre-immunized hamsters.
These results demonstrate that infectious Ad is majorly cleared from tumors by the antiviral T cells rather than antibodies, and the preexisting anti-Ad antibody could not effectively block viral infection of tumor cells. Anti-Ad antibodies might have important role in preventing the systemic toxicity of oncolytic Ad by inhibiting Ad spillover from the tumor and replication in normal tissues (8) . The identical kinetics of viral DNA clearance from the tumor in T cell-deleted or immunocompetent hamsters with or without pre-immunization demonstrate that the adaptive immunity has no effect on the clearance of oncolytic Ad genome, and the innate immunity may be responsible for clearance of virus DNA from tumors following i.t. injection of oncolytic Ad. Most importantly, even though the pre-immunization induced a robust systemic immune response against Ad, the preexisting anti-viral immunity had no effect on the therapeutic efficacy of oncolytic Ad therapy, which is consistent with the previous study (8) Statistical analysis was conducted using 2-way ANOVA test on time points after viral therapy. ***, P<0.001; ns, not significant. 
